Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.3075
Abstract: We conducted an institutional study to compare the clinical and pathological efficacy between the neoadjuvant therapy (NAT)‐modified FOLFIRINOX (mFOLF) vs nanoparticle albumin–bound paclitaxel plus gemcitabine (nab‐P/G) for borderline resectable pancreatic cancer (BRPC) and locally advanced… read more here.
Keywords: surgical resection; modified folfirinox; pancreatic cancer; mfolf ... See more keywords
Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy
Sign Up to like & getrecommendations! Published in 2018 at "Cancers"
DOI: 10.3390/cancers10110454
Abstract: While modified FOLFIRINOX therapy is effective for treating advanced pancreatic cancer, it frequently causes severe neutropenia. The present study investigated the effect of severe neutropenia on clinical outcomes in advanced pancreatic cancer patients who received… read more here.
Keywords: folfirinox therapy; modified folfirinox; advanced pancreatic; severe neutropenia ... See more keywords
Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
Sign Up to like & getrecommendations! Published in 2019 at "World Journal of Gastroenterology"
DOI: 10.3748/wjg.v25.i23.2839
Abstract: Pancreatic cancer is one of the leading causes of cancer death worldwide. Adjuvant chemotherapy has been developed based on the experiences made with palliative chemotherapy, and advocated to improve long-term survival of patients with this… read more here.
Keywords: resected pancreatic; modified folfirinox; pancreatic cancer; cancer ... See more keywords
Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
Sign Up to like & getrecommendations! Published in 2018 at "World Journal of Gastrointestinal Oncology"
DOI: 10.4251/wjgo.v10.i12.505
Abstract: AIM To evaluate the efficacy and safety of modified FOLFIRINOX as a second-line treatment for gemcitabine (GEM)-refractory unresectable pancreatic cancer (PC). METHODS This study was a prospective, multicenter, one-arm, open-label, phase II trial. Patients with… read more here.
Keywords: treatment; modified folfirinox; pancreatic cancer; refractory ... See more keywords